Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 17;52(1):239.
doi: 10.1007/s11033-025-10361-1.

Integrating alternative therapies in overcoming chemotherapy resistance in tumors

Affiliations
Review

Integrating alternative therapies in overcoming chemotherapy resistance in tumors

Sana S Alqarni et al. Mol Biol Rep. .

Abstract

Chemotherapy-resistant tumors present a significant challenge in oncology, often leading to treatment failures owing to mechanisms such as genetic mutations, drug efflux, altered metabolism, and adaptations within the tumor microenvironment. These factors limit the effectiveness of treatment and contribute to tumor resistance. This review highlights the role of alternative therapies aimed at overcoming resistance mechanisms. Several alternative strategies with high efficacy rate against tumor resistance are being explored, including targeted therapies (58-64%), immunotherapy (80%), hormone therapy (22-61%), and emerging approaches such as herbal therapies (90%), probiotics (34-90%), metabolic therapies (> 50%), epigenetic therapies (51-89%), microbiome-based therapies (50%), gene therapy (67-80%), photodynamic therapy/hypothermia (86-99%), and nanotechnology (50-67%). Integrating these alternative strategies with conventional treatments has the potent-al to augment the therapeutic efficacy and patient outcomes. Despite this progress, limitations in cancer therapeutics include the lack of predictive biomarkers, resistance mechanisms, and tumor heterogeneity, all of which contribute to treatment failure and relapse. To address these limitations, advancements in molecular diagnostics, as well as early detection through liquid biopsies, and the use of biomarkers to monitor resistance and guide treatment are crucial. Additionally, expanding clinical trials is essential to validate new therapies and improve patient outcomes.

Keywords: Alternative therapies; Chemotherapy; Combinatorial approaches; Drug resistance; Tumors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interests: The authors declare no competing interests. Ethical approval: Not applicable.

Similar articles

References

    1. WHO. (2024, February 1). Global cancer burden growing, amidst mounting need for services. Retrieved from https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--a...
    1. Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB (2019) Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study, The Lancet. Oncology 20(6):769–780. https://doi.org/10.1016/S1470-2045(19)30163-9 - DOI - PubMed
    1. Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer drug resistance (Alhambra, Calif.), 2(2), 141–160. https://doi.org/10.20517/cdr.2019.10
    1. Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., ... & de la Lastra, J. M. P. (2023). Cancer chemotherapy and beyond Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 10(4): 1367–1401.
    1. Rahman MA, Rakib-Uz-Zaman SM, Chakraborti S, Bhajan SK, Gupta RD, Jalouli M, Parvez MAK, Shaikh MH, Hoque Apu E, Harrath AH et al (2024) Advancements in utilizing natural compounds for modulating autophagy in liver cancer: molecular mechanisms and therapeutic targets. Cells 13(14):1186. https://doi.org/10.3390/cells13141186 - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources